Main content
Immunity after COVID-19 vaccination: a scoping review
- Nina Kreuzberger
- Caroline Hirsch
- Marike Andreas
- Lena Böhm
- Paul J Bröckelmann
- Veronica Di Cristanziano
- Martin Golinski
- Verena Kappler
- Florian Klein
- Berit Lange
- Joerg J Meerpohl
- Agata Mikolajewska
- Onnen Mörer
- Ina Monsef
- Yun Soo Park
- Vanessa Piechotta
- Carolin Prinz
- Isti Rodiah
- Susanne Salomon
- Leif Erik Sander
- Christoph Schmaderer
- Miriam Stegemann
- Caspar Stephani
- Kanika Vanshylla
- Stephanie Weibel
- Nicole Skoetz
Date created: | Last Updated:
: DOI | ARK
Creating DOI. Please wait...
Category: Project
Description: The objective of the planned scoping review is to provide an overview on the existing literature on immune response and long-term efficacy outcomes after COVID-19 vaccination, and to map this evidence according to the examined populations, specific vaccines, immunity parameters and their way of determining relevant long-term outcomes and the availability of mapping between immune reactivity and relevant outcomes. We will limit inclusion to literature on the four vaccines currently authorized by the EMA and vaccines authorized in at least 10 countries worldwide: • Comirnaty [Pfizer / Biontech], • Spikevax [Moderna], and its equivalent TAK-919 [Moderna formulation, Takeda] • Vaxzevria [Oxford / AstraZeneca] and its equivalent Covishield [Oxford / AstraZeneca formulation, Serum Institute of India] • COVID-19 Vaccine Janssen [Ad26.COV2.S] • Sputnik V [Gamaleya] • Sputnik Light [Gamaleya] • BBIBP-CorV (Vero Cells) [Sinopharm (Beijing)] • CoronaVac [Sinovac] (COVID-19 Vaccine (Vero Cell) Inactivated)
Start managing your projects on the OSF today.
Free and easy to use, the Open Science Framework supports the entire research lifecycle: planning, execution, reporting, archiving, and discovery.